Consultation on the amendment to the GB approval (acute reference dose ARfD) of active substance Flonicamid.
Deadline for comments: Date 2023
This consultation relates to GB’s Decision Assessment Report (DAR) for the active substance Flonicamid.
The dossier for the amendment to the approval of this active substance in Great Britain under retained Regulation 1107/2009 was submitted by ISK Biosciences Europe N.V. (“ISK”), with the assessment performed by the Chemicals Regulation Division of the Health and Safety Executive.
Comments are invited on the content and conclusions of the DAR and can be submitted by any member of the public or interested party.
Certain specified confidential information that relates to the active substance is not published as part of this consultation.
Comments on the GB’s assessment reports should be submitted by using the online survey below, no later than the deadline above. Please cite the relevant page numbers in the DAR sections in relation to your comment along with the section header/sub-heading of the data point.
We will not consider comments if they:
HSE will assess and publish all comments which are submitted in line with the criteria above.
Share
Share on Twitter Share on Facebook